In their press release, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced that an ongoing Phase II proof-of-concept trial evaluating an investigational 8 mg dose of… Read More »Regeneron announces that its high-dose aflibercept (8mg) has met primary end-point in Phase II data for wet AMD.
Researchers from King’s College London, UK have published a systematic review and meta-analysis on individual participant data from RCT literature using evidence on ocriplasmin’s effect… Read More »A systematic review and meta-analysis on individual participant data, within 5 RCTs, on the treatment of ocriplasmin for vitreomacular adhesion resolution.
A recent research presentation from a clinical ophthalmology group in UCLA has reported that “e-cigarette” smoking is associated with visual impairment in the Behavioral Risk… Read More »Survey data on E-cigarette use from >1 million participants shows concerns about visual impairment.
September 5th, 2021: “EURETINA-Brief”© Issue No. 242 by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the… Read More »
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the December 18th, 2019 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »December 18th, 2019: “EURETINA-Brief”© Issue No. 204
Genetics and Genomics of Eye Disease, 1st Edition – Advancing to Precision Medicine (Elsevier) Editors: Xiaoyi Gao Paperback ISBN: 9780128162224 eBook ISBN: 9780128167274; Pages 383,… Read More »Genetics and Genomics of Eye Disease, 1st Edition – Advancing to Precision Medicine (Elsevier) Editors: Xiaoyi Gao Ph.D.
Researchers at the Sydney Institute of Vision Science, in New South Wales, Australia report that good long-term efficacy of anti-VEGF therapy over 5 years provides… Read More »Five-year outcomes of retinal vein occlusion provide long term data for anti-VEGF treatments on real-world data
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the April 16th, 2019 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »April 16th, 2019: “EURETINA-Brief” Issue No. 190
Editas Medicine, Inc. (NASDAQ: EDIT), based in Dublin, Ireland and Cambridge, Massachusetts, and Allergan plc (NYSE: AGN), also headquartered in Dublin, Ireland have announced the… Read More »Editas Medicine Inc. (NASDAQ:EDIT), and Allergan plc (NYSE:AGN), progress option rights to develop CRISPR technology for treatment of LCA 10
EURETINA, through a collaboration with Fight for Sight, have announced a dedicated Research Call to support clinical research in the field of sub-macular haemorrhage (SMH),… Read More »***EURETINA / Fight for Sight launch Sub-Macular Haemorrhage (SMH) Clinical Research Call***